Privately-held German firm Boehringer Ingelheim has acquired Berlin-based biotech ICD Therapeutics for an undisclosed sum, including its innovative MacroDel biologics delivery platform.
Boehringer has previously supported ICD’s development of the MacroDel technology through its investment arm, the Boehringer Ingelheim’s Venture Fund (BIVF).
The firm plans to deploy the platform for the development of novel therapeutics, in collaboration with nanoPET Pharma, a former shareholder of ICD Therapeutics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze